Key Points
- Nazneen Rahman, an AstraZeneca insider, sold 297 shares on December 18 at an average price of £134.96 for a total of £40,083.12, a relatively small transaction versus AstraZeneca's £210.87 billion market cap.
- Analysts give AstraZeneca a consensus rating of Moderate Buy with an average target of £138 (individual targets £140–£150), and the stock trades at a PE of 22.59 with 50-/200-day moving averages of £132.38 and £119.43 respectively.
AstraZeneca PLC (LON:AZN - Get Free Report) insider Nazneen Rahman sold 297 shares of AstraZeneca stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of £134.96, for a total value of £40,083.12.
AstraZeneca Price Performance
Shares of AstraZeneca stock opened at £136.02 on Tuesday. The company has a current ratio of 0.93, a quick ratio of 0.59 and a debt-to-equity ratio of 73.83. The firm has a market capitalization of £210.87 billion, a PE ratio of 22.59, a price-to-earnings-growth ratio of 0.86 and a beta of 0.17. The business's 50-day moving average price is £132.38 and its 200-day moving average price is £119.43. AstraZeneca PLC has a 12 month low of GBX 9,573.51 and a 12 month high of £142.06.
Analysts Set New Price Targets
Several research analysts have commented on AZN shares. Berenberg Bank lifted their price target on shares of AstraZeneca from £142 to £145 and gave the stock a "buy" rating in a research note on Tuesday, October 21st. Shore Capital reaffirmed a "buy" rating and issued a £145 price objective on shares of AstraZeneca in a research note on Thursday, November 6th. JPMorgan Chase & Co. reiterated an "overweight" rating and issued a £140 target price on shares of AstraZeneca in a research report on Thursday, December 4th. Finally, Jefferies Financial Group reissued a "buy" rating and issued a £150 price target on shares of AstraZeneca in a research note on Monday, November 10th. Four analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of £138.
Read Our Latest Research Report on AstraZeneca
About AstraZeneca
(
Get Free Report)
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
